About ARCA Biopharma, Inc.
ARCA biopharma, Inc. | 788 followers on LinkedIn. Pharmacogenetic Precision Medicine for Cardiovascular Diseases
| ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA’s lead development program is intended to be a direct implementation of those ideas. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF).
|
|
|
1-10 employees
View all ARCA Biopharma, Inc. employees
|
|
Biotechnology
|
|
720-940-2100
|
|
Suite 100,Westminster,Colorado,US
|
|
None
|
|
Drug Development, Cardiology, Clinical Trials, Precision Medicine, Cardiovascular Disease, Personalized Medicine, Heart Failure, Atrial Fibrillation, Pharmacogenetics, Covid-19, Coronavirus, Rna-Associated Disease
|
ARCA Biopharma, Inc. Alternatives
ARCA Biopharma, Inc. Staff Directory
Search ARCA Biopharma, Inc. Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
